Cargando…

Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy

PURPOSE: Myeloproliferative neoplasms (MPNs) have been associated with increased systemic levels of vascular endothelial growth factor (VEGF). This study investigated an association between systemic busulfan for treatment of MPN and the requirement for intravitreal anti-VEGF injections for treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalvin, Lauren A., Olsen, Timothy W., Bakri, Sophie J., McCullough, Kristen, Tefferi, Ayalew, Al-Kali, Aref
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Image
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058582/ https://www.ncbi.nlm.nih.gov/pubmed/35509281 http://dx.doi.org/10.1016/j.ajoc.2022.101554

Ejemplares similares

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
por: Tefferi, Ayalew
Publicado: (2009)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Physico-Chemical Stability of Busulfan in Injectable Solutions in Various Administration Packages
por: Houot, Mélanie, et al.
Publicado: (2013)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Renal cell carcinoma metastasizing to the myeloproliferative bone marrow
por: Oo, Thein Hlaing, et al.
Publicado: (2018)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Intratesticular versus intraperitoneal injection of Busulfan for the induction of azoospermia in a rat model
por: Mobarak, Halimeh, et al.
Publicado: (2022)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

AKT is a therapeutic target in myeloproliferative neoplasms
por: Khan, Irum, et al.
Publicado: (2013)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Myeloproliferative invasion of arterial walls: Premortem diagnosis by temporal artery biopsy
por: Van Steenberge, Hannah, et al.
Publicado: (2021)

Bilateral venous stasis retinopathy
por: Mansukhani, Sasha A., et al.
Publicado: (2020)

Pulmonary hypertension associated with busulfan
por: Hagenburg, Jean, et al.
Publicado: (2021)

Establishing a nonlethal and efficient mouse model of male gonadotoxicity by intraperitoneal busulfan injection
por: Xie, Yun, et al.
Publicado: (2019)

Effects of intravenous multiple busulfan injection on suppression of endogenous spermatogenesis in recipient stallion testes
por: Jung, Heejun, et al.
Publicado: (2021)

Targeting megakaryocytic induced fibrosis by AURKA inhibition in the myeloproliferative neoplasms
por: Wen, Qiang Jeremy, et al.
Publicado: (2015)

Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience
por: Gangat, Naseema, et al.
Publicado: (2022)

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients
por: Fan, N., et al.
Publicado: (2018)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Leukostasis retinopathy treated with Anti-VEGF therapy
por: Shakibai, Nasim, et al.
Publicado: (2020)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

Testicular Busulfan Injection in Mice to Prepare Recipients for Spermatogonial Stem Cell Transplantation Is Safe and Non-Toxic
por: Qin, YuSheng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bv5ao8k79bp73b79f4ac7sv3kk